Development and partial characterization of a human T-lymphoblastic leukemic (CCRF-CEM) cell line resistant to etoposide. Analysis of possible circumventing approaches

Journal of Chemotherapy

Volumn 8, Issue 6, 1996, Pages 465-471

  Flandina, C ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

atypical multidrug resistance; circumvention; human T lymphoblastic CCRF CEM leukemia; leukemia; resistance

Indexed keywords

ALPHA INTERFERON; AMSACRINE; BRYOSTATIN; BUTHIONINE SULFOXIMINE; CISPLATIN; DOXORUBICIN; ETOPOSIDE; GLUCOCORTICOID; INTERLEUKIN 1; MITOXANTRONE; NOVOBIOCIN; PENTOXIFYLLINE; PHORBOL ESTER; RAZOXANE; TUMOR NECROSIS FACTOR ALPHA; VINCRISTINE;

ARTICLE; CROSS RESISTANCE; DRUG RESISTANCE; HUMAN; HUMAN CELL; LEUKEMIA CELL; LYMPHATIC LEUKEMIA; MULTIDRUG RESISTANCE; PHENOTYPE;

EID: 0030449487     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.1996.8.6.465     Document Type: Article

References (21)

1. Beck WT, Cirtain MC, Danks MK, et al. Pharmacological, molecular and cytogenetic analysis of "atypical" multidrug-resistant human leukemic cells. Cancer Res 1987; 47: 5455-5460.
2. Morrow CS, Kowan KM. Mechanisms and clinical significance of multidrug resistance. Oncology 1988; 2: 55-67.
3. De Isabella P, Capranico G, Zunino F. The role of topoisomerase II in drug resistance. Life Sci 1991; 48: 2195-2205.
4. D'Alessandro N, Borsellino N, Leonardi V, Crescimanno M. Immunological implications of tumour drug resistance. Forum Trends Exp Clin Med 1994; 4: 124-143.
5. Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy- induced apoptosis in a human leukemia cell line. Blood 1993; 81: 151-157.
6. L is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis. Cancer Res 1995; 55: 2576-2582.
7. Borsellino N, Belldegrun A, Bonavida B. Endogenous interleukin- 6 is a resistance factor for cis-diamminedichloro-platinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res 1995; 55: 4633-4639.
8. Calabresi P, Chabner BA. Antineoplastic agents. In: Gilman AG, Rail TW, Nies AS, Taylor P, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics, New York,-Pergamon Press, 1990: 1209-1263.
9. Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF. Adriamycin- induced DNA damage mediated by mammalian topoisomerase II. Science (Washington DC) 1984; 226: 466-468.
10. Lock RB, Ross WE. DNA topoisomerases in cancer therapy. Anticancer Drug Des 1987; 2: 151-164.
11. Zwelling LA. Topoisomerase II as a target of antileukemia drugs: a review of controversial areas. Hematol Pathol 1989; 3: 101-112.
12. Schneider E, Hsiang YH, Liu LF. DNA topoisomerases as anticancer drug targets. Adv Pharmacol 1990; 149-183.
13. Fingert HJ, Pu AT, Chen Z, Googe PB, Alley MC, Pardee AB. In vivo and in vitro enhanced antitumor effects of pentoxifylline in human cancer cells treated with thiotepa. Cancer Res 1988; 48: 4375-4381.
14. Kraft AS. Bryostatin 1: will the oceans provide a cancer cure? J Natl Cancer Inst 1993; 85: 1790-1792.
15. Dufour P, Feugeas O, Bergerat JP, Oberling F. Modulation of adriamycin cytotoxicity on K562 and K562 adri by Interferon alpha, all trans retinoic acid and their combination. Proc Am Assoc Cancer Res 1994; 35: 282.
16. Lippman SM, Glisson BS, Kavanagh JJ, et al. Retinoic acid and Interferon combination studies in human cancer. Eur J Cancer 1993; 29A (Supplement 5): S9-S13.
17. Leonardi V, Borsellino N, Crescimanno M, Flandina C, Flugy A, D'Alessandro N. Combinative growth inhibitory effects of interferon-alpha and doxorubicin on multidrug resistant tumor cell lines. Oncol Rep 1994; 1: 93-95.
18. Salmon SE, Soehnlen B, Dalton WS, Meltzer P, Scuderi P. Effect of tumor necrosis factor on sensitive and multidrug resistant human leukemia and myeloma cell lines. Blood 1989; 74: 1723-1727.
19. Borsellino N, Crescimanno M, Flandina C, Flugy A, D'Alessandro N. Combined activity of interleukin-lalpha or TNF-alpha and doxorubicin on multidrug resistant cell lines: evidence that TNF and DXR have synergistic antitumor and differentiation-inducing effects. Anticancer Res 1994; 14: 2643-2648.
20. Deffie AM, Batra JK, Goldenberg GJ. Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin-sensitive and -resistant P388 leukemia cell lines. Cancer Res 1989; 49: 58-62.
21. De Isabella, Capranico G, Binaschi M, Tinelli S, Zunino F. Evidence of DNA topoisomerase II-dependent mechanisms of multidrug resistance in P388 leukemia cells. Mol Pharmacol 1990; 37: 11-16.